Virtual Event from SelectBio: Academic Drug Discovery 2016
Reporter: Stephen J. Williams, PhD
Virtual Event from SelectBio
Academic Drug Discovery 2016
Registration to this Virtual Event is free of charge and gives you 180 days access. You will be sent details of how to access the event via email after registration.
For more information please click here.
Talks
 |
Academic Drug Discovery: Opportunities For Challenging Targets In Oncology Olivia Rossanese, Head of Biology and Reader, CR UK Cancer Therapeutics Unit, Institute of Cancer ResearchThe Cancer Research UK Cancer Therapeutics Unit at the Institute of Cancer Research is a multidisciplinary drug discovery group with a focus on novel, high-risk targets in cancer. This class of targets comes with unique challenges, such as a higher target validation burden or increased technical risk, but presents distinct opportunities for discovering novel biology and innovative medicines. |
 |
Academics and academic institutions need to pull together, to help generate more novel medicines for patients Chas Bountra, Chief Scientist, University of OxfordAcademics and academic institutions need to pull together, to help generate more novel medicines for patients. Together, we are creating a new ecosystem for drug discovery. One which we believe will accelerate the generation of more novel medicines, more quickly. We hope these will also be more affordable. |
 |
Chemical Proteomics: Accelerating Academic Target Discovery And Validation Edward Tate, Professor of Chemical Biology, Imperial College LondonMy group develops chemical biology approaches to identify and validate potential drug targets, particularly in the field of protein post-translational modification. In this talk I will present our recent research on developing chemical probes for protein lipidation, which has led to fundamental biological insights into the scope and roles of these modifications in disease biology, and to drug development projects in infection and cancer. |
 |
Institute For Applied Cancer Science, Developing The Next Generation Of Oncology Agents For Targeted Patient Populations Philip Jones, Head of Drug Discovery, Institute for Applied Cancer Science. MD Anderson Cancer Center, University of Texas MD Anderson Cancer CenterThe Institute for Applied Cancer Science (IACS) is a fully integrated drug discovery and development unit embedded within MD Anderson. By housing an innovative drug development operation within the world’s leading cancer center, we are surrounded by the culture of innovative academic science and clinical excellence for which MD Anderson is known. |
 |
Opening “The Box of Delights” – Accessing Pharma to Enhance Academic Drug Discovery Justin Bryans, Director of Drug Discovery, Medical Research Council TechnologyThis presentation will describe some of the ground breaking collaborations between MRC Technology and various Pharma companies, highlighting why these are so important to each party, and how these collaborations will drive innovative drug discovery and deliver new treatments to patients. |
 |
Small Molecules That Stabilize And Activate Lipoprotein Lipase (LPL) Mikael Elofsson, Professor, University of UmeåThe presentation covers a screening-based approach to identify small molecules that stabilize and activate lipoprotein lipase, a key enzyme in lipid metabolism. A medicinal program led to improved compounds with efficacy in vivo. |
2012pharmaceutical
Amandeep Kaur
Aashir Awan, Phd
Abhisar Anand
Adina Hazan
Alan F. Kaul, PharmD., MS, MBA, FCCP
alexcrystal6
anamikasarkar
apreconasia
aptubman
Arav Gandhi
aviralvatsa
David Orchard-Webb, PhD
danutdaagmailcom
Demet Sag, Ph.D., CRA, GCP
Dror Nir
dsmolyar
Ethan Coomber
evelinacohn
Gail S Thornton
Irina Robu
jayzmit48
jdpmd
jshertok
kellyperlman
Ed Kislauskis
larryhbern
Madison Davis
marzankhan
megbaker58
ofermar2020
Dr. Pati
pkandala
ritusaxena
Rick Mandahl
sjwilliamspa
Srinivas Sriram
stuartlpbi
Dr. Sudipta Saha
tildabarliya
zraviv06
zs22
Leave a Reply